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disorders and which has on occasion been associated with
the progressive development of one or other malignancy.
Further investigation of patients may well show the occurrence
of common pathogenetic mechanisms.
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The value of abrasive
cytology in the early
detection of oesophageal
carcinoma
A pilot survey in Ciskei
C. Lazarus, K. Jaskiewicz, H. A. Southall,
R. A. Sumeruk, J. Nainkin
The use of abrasive cytology as a screening procedure in
the diagnosis of early cancer of the oesophagus among
asymptomatic rural Ciskeians was assessed. An
inexpensive, locally man~factured brush biopsy caPSUle
was used to obtain cytological material from 1 336
subjects. The technique gives a high yield, has a high
predictive value and identifies a high prevalence of .
sufferers at the detectable preclinical phase of the
disease.
S Afr Med J 1994; 84: 488-490.
Squamous cancer of the oesophagus is the commonest
cancer among black men in southern Africa. Only cancer of
the cervix among black women is more prevalent.' It was
especially common among rural Transkeians,' but is now
also found increasingly in urban populations of the region!-6
As a rule, patients with oesophageal cancer present at an
advanced stage of relentless progression. While patients'
symptoms are usually of recent origin, their period of
survival is shortY This cancer therefore seems to fulfil many.
of the criteria necessary for it to be suitable for screening.
These include: (i) a high prevalence in a susceptible
population; (H) its recognition as a serious disease in the
community; (Hi) effectiveness of cancer therapy, either by
means of surgery or radiotherapy; and (iv) a well-
documented, prolonged 'detectable pre-c1inical phase'
(DPCP) when effective therapy could lead to a cure.~
Abrasive brush cytology as a screening technique for
oesophageal cancer has been used for many years in high-
incidence areas of China. Early diagnosis and many long-
term survivors have been reported.'O,l1 In southern Africa,
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brush cytology has also been used as a diagnostic aid and
research tool. 12•15 In one study 15 asymptomatic
oesophageal cancer patients were identified by means of
brush cytology with an inflatable balloon catheter. ,. However,
brush cytology has not been used in mass screening.
This pilot study was undertaken to determine the
feasibility of brush cytology with a simple, inexpensive brush
biopsy capsule as a screening programme for oesophageal
cancer in asymptomatic rural subjects from Ciskei.
Subjects and methods
Villages in the Keiskammahoek district of Ciskei were visited
between 1986 and 1990. In most cases the villages selected
were those with high oesophageal cancer prevalence rates,
as estimated from case records at Cecilia Makiwane
Hospital (unpublished data). The co-operation of local
chiefs, headmen and community leaders was sought, and
adult villagers were invited to participate in the study.
The brush biopsy capsule used is an inexpensive, locally
manufactured capsule similar to that described by Nabeya.17
It consists of a sponge within a capsule attached to a long
thread. The subjects swallow the capsule with some water.
The capsular covering of the sponge dissolves within 10
minutes and the sponge expands within the stomach; this
allows it to obtain cytological material when it is withdrawn
through the oesophagus. The material thus obtained is
smeared onto a glass slide, fixed, stained and examined
cytologically.
Subjects who were experiencing difficulty with swallowing
or in whom the capsule failed to reach the stomach (as
assessed by the length of thread remaining outside the
mouth) were excluded from the study and referred for other
investigations. The few subjects from whom no suitable
material for cytological examination was obtained were
excluded from the study.
All subjects with cytological reports of severe dysplasia or
carcinoma underwent endoscopy with Lugol staining of the
oesophagus.,··,9 Those whose diagnosis of carcinoma was
confirmed histologically were counselled and referred for
further investigation and treatment. In order to evaluate the
predictive value, the detected prevalence of the DPCP and
the yield of the test, the following definitions were used: true
positive - subjects whose results were cytologically
positive for cancer with the result confirmed by means of
endoscopy and biopsy; false positive - subjects whose
results were cytologically positive for oesophageal cancer
but which were not confirmed by endoscopy and biopsy;
predictive value - among subjects positive on the
screening test, the proportion found by subsequent




True positives + false positives 1
The detected prevalence of the DPCP among all
subjects screened, was the proportion found on the
screening test and subsequent diagnostic evaluation to have
the disease. The yield entailed the number of tests that had
to be done in order to identify 1 person whose prognosis
would be improved as a result of the screening programme.
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The study was approved by the Committee for Research
at Cecilia Makiwane Hospital and by the Department of
Health of the Ciskei.
Results
One thousand three hundred and thirty-six subjects (926
women and 410 men) underwent the procedure. They were
representative of the usual week-day resident population of
the Villages, with large numbers of older subjects present.
Of the 1 336 subjects, 9 true-positive cases were detected.
A further subject reported as positive by the pathologist
revealed a diffuse, granular oesophagus at endoscopy but
histology of the biopsy specimens revealed acanthotic,
dysplastic epithelium without invasion. This subject has
been regarded as a false positive.
The predictive value of the programme as determined in
this study is therefore:
9 100
--x-- =90%.
9 + 1 1
The detected prevalence of the DPCP was 9 out of 1 336
subjects brushed.
The 9 subjects whose carcinoma was confirmed
histologically were counselled and referred for further
investigations and treatment. In 7 cases the carcinoma was
at an early stage while in 3 it was advanced. Two of the
subjects with early carcinoma were old and infirm and so
received no further treatment. Three other SUbjects declined
intervention despite counselling. Only 2 of the 9 subjects
underwent the recommended treatment.
The yield of this study is therefore strictly 2 cases (668
screens per case treated) but the programme yield could
potentially increase to 9/1 336 (148 screens per case).
Discussion
The aim of screening for cancer is to detect and treat the
disease at a stage when it is still curable. In practice this
implies the detection of the cancer before it is clinically
evident. While the idea that detection of a disease in a pre-
clinical phase will be beneficial has a strong intuitive appeal,
the value of screening as a means of cancer control remains
controversial.
While the major benefit would appear to be an improved
prognosis, the disadvantages are significant. These include
the expense of the screening programme, diagnostic
investigations and treatment, the time and discomfort of
those screened, a longer period of morbidity for those found
to have the disease and the overtreatment of borderline
cases. In addition, inappropriate reassurance will be given to
'false-negative' subjects and unnecessary anxiety
engendered among 'false-positive' subjects.
Hence, any effective screening programme needs to be
inexpensive, easy to implement and well tolerated by those
tested. In addition, the screening technique itself needs to
be reliable and the results readily reproducible.
The procedure of obtaining cytological material by brush
biopsy capsule was reasonably well tolerated by most
subjects. Little difficulty was experienced when the capsule
SAMJ Volllme 84 No.8 AlIgllst /994
was swallowed, although subjects usually 'gag' when the
sponge is retrieved and a few subjects vomited at the same
time. Apart from a mild sore throat in some, no pain was
experienced.
While the brush biopsy capsule has been known to lodge
in the oesophagus above an advanced carcinoma and so
fail to obtain malignant cells when withdrawn,'o our study
suggests that the technique can establish the diagnosis in
asymptomatic patients. Although some field-workers
responsible for performing the survey had relatively little
training, material suitable for cytological assessment was
obtained in almost all cases.
Although the brush biopsy capsule itself is inexpensive
(R1/capsule approx.), the hidden costs (field workers,
transport, preparation of slides and cytological assessment),
while difficult to evaluate, are considerable. The high
detected prevalence (9/1 336 subjects) may in part be
explained by the large number of older individuals assessed,
in whom the disease would be more likely to be present.
However, it is possible that the specific villages chosen for
the survey because of their apparent high mortality rates for
oesophageal cancer did, in fact, have an unusually high
prevalence of the disease.
The validity of brush cytology as a screening test may be
assessed in terms of its sensitivity and specificity."2' In this
study, it was not possible to make the distinction between
true- and false-negative subjects necessary for this
assessment. To administer the confirmatory test to
apparently healthy subjects whose screening test was
negative is ethically unacceptable and economically
impractical." Predictive value among those subjects positive
for the screening test is the proportion confirmed as having
the disease in question. For a disease such as oesophageal
cancer the major determinants of predictive value are the
prevalence of the DPCp, the specificity of the test and, to a
lesser extent, its sensitivity." A high predictive value
indicates that the programme appears to be satisfactory.
The high predictive value of 90% obtained in this survey
suggests that the programme is satisfactory; the test has a
high specificity and confirms a sufficiently high prevalence in
the population screened.
The yield is the number of tests which must be performed
to identify 1 case" and is useful in justifying (or not) the cost
of the screening programme in relation to the value of the
cases successfully treated. -
This pilot survey suggests that brush cytology as a means
of screening for oesophageal cancer in southern Africa may
be as valuable a tool in the control of this disease as it has
been in China, provided that screening is accompanied by
an intensive community-based health education programme.
In this study, 5 subjects whose general health was good
were assessed as having 'early carcinoma' and were
encouraged to undergo appropriate therapy. Despite
adequate counselling, 3 of the 5 declined any further
treatment. This is due to the community's observation that
most patients undergoing surgery or radiotherapy for cancer
eventually die and that treatment aggravates the condition.
Thus to treat a cancer which is, as yet, not producing any
symptoms is unacceptable. Community acceptance of
subsequent treatment is therefore an essential prerequisite
of any screening programme.
Results of studies conducted in high-risk patients in
Chicago" suggest limited use of brush cytology as a
screening method for the early detection of oesophageal
carcinoma. On the other hand, the efficacy of oesophageal
cancer screening has been adequately documented in
China. This survey suggests that this could be true for
southern Africa. We recommend that economic and
educational implications of mass screening for this disease
be investigated by health authorities with the enthusiasm
that we believe would be present if a disease of such
prevalence was to affect the First-World population of the
region.
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